Failure to Satisfy Listing Rule Form 8 K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 8, 2025, Gain Therapeutics Inc. (the "Company") received a letter (the "MVLS Deficiency Notice") from the listing qualifications department staff (the "Staff") of The Nasdaq Stock Market ("Nasdaq") notifying the Company that that from November 14, 2024 to December 27, 2024, the Company's Market Value of Listed Securities ("MVLS") was below the minimum of $50 million required for continued listing on The Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the "MVLS Requirement").

The MVLS Deficiency Notice had no immediate effect on the listing of the Company's common stock, and the Company's common stock continues to trade on the Nasdaq Global Market under the symbol "GANX."

As of January 14, 2025, the Company has regained compliance with the MVLS Requirement and the Staff has provided written confirmation of compliance on January 15, 2025. The matter is now closed.